Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

98 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Principles and clinical application of assessing alterations in renal elimination pathways.
Tett SE, Kirkpatrick CM, Gross AS, McLachlan AJ. Tett SE, et al. Among authors: gross as. Clin Pharmacokinet. 2003;42(14):1193-211. doi: 10.2165/00003088-200342140-00002. Clin Pharmacokinet. 2003. PMID: 14606929 Review.
Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity.
Loboz KK, Gross AS, Williams KM, Liauw WS, Day RO, Blievernicht JK, Zanger UM, McLachlan AJ. Loboz KK, et al. Among authors: gross as. Clin Pharmacol Ther. 2006 Jul;80(1):75-84. doi: 10.1016/j.clpt.2006.03.010. Clin Pharmacol Ther. 2006. PMID: 16815319 Clinical Trial.
Measurement of CYP1A2 activity: a focus on caffeine as a probe.
Perera V, Gross AS, McLachlan AJ. Perera V, et al. Among authors: gross as. Curr Drug Metab. 2012 Jun 1;13(5):667-78. doi: 10.2174/1389200211209050667. Curr Drug Metab. 2012. PMID: 22554278 Review.
Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol.
Gross AS, McLachlan AJ, Minns I, Beal JB, Tett SE. Gross AS, et al. Br J Clin Pharmacol. 2001 Jun;51(6):547-55. doi: 10.1046/j.1365-2125.2001.01390.x. Br J Clin Pharmacol. 2001. PMID: 11422014 Free PMC article. Clinical Trial.
The renal clearance of each marker (mean+/- s.d.) was calculated as the ratio of the amount excreted in urine and the area-under-the-concentration-time curve. ...RESULTS: The renal clearances of sinistrin (M: 119 +/- 31 ml min(-1); M + F: 130 +/- 40 ml min(-1); P = 0.32), …
The renal clearance of each marker (mean+/- s.d.) was calculated as the ratio of the amount excreted in urine and the area-under-the- …
HPLC assay for bupropion and its major metabolites in human plasma.
Loboz KK, Gross AS, Ray J, McLachlan AJ. Loboz KK, et al. Among authors: gross as. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Sep 5;823(2):115-21. doi: 10.1016/j.jchromb.2005.06.009. J Chromatogr B Analyt Technol Biomed Life Sci. 2005. PMID: 16011913
Bupropion is used clinically as an antidepressant and in smoking cessation. As it is metabolised to hydroxybupropion specifically by CYP2B6, bupropion has also been used as a probe to assess CYP2B6 activity. ...The inter- and intra-day assay variability (meas …
Bupropion is used clinically as an antidepressant and in smoking cessation. As it is metabolised to hydroxybupropion specifica …
Stereoselective analysis of hydroxybupropion and application to drug interaction studies.
Xu H, Loboz KK, Gross AS, McLachlan AJ. Xu H, et al. Among authors: gross as. Chirality. 2007 Mar;19(3):163-70. doi: 10.1002/chir.20356. Chirality. 2007. PMID: 17167747
The method was reproducible as both interday and intraday variabilities were less than 10% for both hydroxybupropion enantiomers. ...
The method was reproducible as both interday and intraday variabilities were less than 10% for both hydroxybupropion enantiomers. ...
In-vitro potencies of histamine H2-receptor antagonists on tetraethylammonium uptake in rat renal brush-border membrane vesicles.
Somogyi AA, Simmons N, Gross AS. Somogyi AA, et al. Among authors: gross as. J Pharm Pharmacol. 1994 May;46(5):375-7. doi: 10.1111/j.2042-7158.1994.tb03816.x. J Pharm Pharmacol. 1994. PMID: 8083810
To determine the potential for competition for the transporter between these drugs and other drugs, their inhibitory potencies were assessed in-vitro, using rat renal brush-border membrane vesicles and tetraethylammonium as the substrate. ...
To determine the potential for competition for the transporter between these drugs and other drugs, their inhibitory potencies were assessed …
Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination.
Elliot DJ, Suharjono, Lewis BC, Gillam EM, Birkett DJ, Gross AS, Miners JO. Elliot DJ, et al. Among authors: gross as. Br J Clin Pharmacol. 2007 Oct;64(4):450-7. doi: 10.1111/j.1365-2125.2007.02943.x. Epub 2007 May 22. Br J Clin Pharmacol. 2007. PMID: 17517049 Free PMC article.
Influence of environmental and genetic factors on CYP1A2 activity in individuals of South Asian and European ancestry.
Perera V, Gross AS, McLachlan AJ. Perera V, et al. Among authors: gross as. Clin Pharmacol Ther. 2012 Oct;92(4):511-9. doi: 10.1038/clpt.2012.139. Epub 2012 Sep 5. Clin Pharmacol Ther. 2012. PMID: 22948892
Significantly lower CYP1A2 activity was observed in South Asian participants (median: 0.42; range: 0.10-1.06) as compared with European participants (0.54; 0.12-1.64) (P < 0.01). ...
Significantly lower CYP1A2 activity was observed in South Asian participants (median: 0.42; range: 0.10-1.06) as compared with Europe …
The effect of liver disease and food on plasma MEGX concentrations.
Pritchard-Davies R, Gross AS, Shenfield GM. Pritchard-Davies R, et al. Among authors: gross as. Br J Clin Pharmacol. 1994 Mar;37(3):298-301. doi: 10.1111/j.1365-2125.1994.tb04279.x. Br J Clin Pharmacol. 1994. PMID: 8198941 Free PMC article. Clinical Trial.
98 results
Jump to page
Feedback